US Oncologist Survey: Optimizing Treatment for Advanced Melanoma


November 2, 2011
50 Pages - SKU: TAG3958723
License type:
Countries covered: United States

This report will help identify current physician practice patterns, understand differences in clinical decisions and the factors that influence those decisions, barriers to optimal patient care, and will provide actionable data for developing marketing strategies. The Assessment Group develops patient vignette surveys to determine the current practice patterns, knowledge, attitudes, confidence and barriers of physicians. Patient cases describe the patient’s history, age, gender, race, and lab/physical results. Following each case, a series of clinical questions is posed to the physicians regarding their treatment decisions. In addition to the cases and clinical questions, questions are designed to assess attitudes, confidence, and barriers to the optimal management of patients.


Executive Summary
Chapter 1: Introduction
Table 1. Treatment Options in Advanced Melanoma
Chapter 2: Respondent Demographics
Table 2. Eligibility Criteria for Survey Participation
Medical specialty
Attended medical school in the US
Gender of survey respondents
Geographic settings
Practice settings
Minimal acceptable level of evidence in determining treatment regimen
Chapter 3: Treatment of Stage III Melanoma with Micrometastatic Axillary Nodes
Confidence in treating this patient to an optimal outcome
Next step in management
Laboratory studies to order
First-line chemotherapy regimen
Factors influencing treatment decision
Second-line treatment regimen
Factors influencing treatment decision
Chapter 4: Treatment of Elderly Woman with Metastatic Disease at the Time of Diagnosis
Confidence in treating this patient to an optimal outcome
Laboratory studies to order
BRAF Mutation Description
First-line chemotherapy regimen
Expected response rate with vemurafenib (PLX4032)
Anticipated complications expected following treatment with vemurafenib (PLX4032)
Chapter 5: Young Man with Recurrent Melanoma Metastatic to Liver and Bone
Confidence in treating this patient to an optimal outcome
Laboratory studies to order
First-line chemotherapy regimen
Mechanism of action of Yervoy (ipilimumab)
Managing side effect of treatment
Next step in management
Proprietary and confidential report prepared by The Assessment Group | 2090 Columbiana Road, Ste 4700 | Birmingham, AL 35216 | 205-776-2701
Reproducation without prior written permission, in any media now in existence or hereafter developed in whole or in any part, is strictly prohibited.
Page 5
Chapter 6: Patient with solitary metastatic lesion
Confidence in treating patient to an optimal outcome
First-line chemotherapy regimen
Factors influencing treatment decisions
Next step in management
Barriers to an optimal outcome
Chapter 7: Summary
Appendix A: Survey Instrument

More Oncology/Hematology reports by The Assessment Group

US Market Changes in the Treatment of Advanced Melanoma by The Assessment Group
Progressively unfolding patient case scenarios were presented to 200 U.S. oncologists, who manage patients with advanced melanoma, to understand differences in clinical decisions and the ...
US Market Changes in the Treatment of Non-Hodgkin's Lymphoma by The Assessment Group
The purpose of this research study is to examine the current and evolving practice patterns of oncologists in managing advanced non-Hodgkin’s lymphoma. A survey ...
US Market Changes in the Treatment of Advanced Prostate Cancer by The Assessment Group
Progressively unfolding patient case scenarios were presented to 151 U.S. oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. ...
US Market Changes in the Treatment of Advanced Lung Cancer by The Assessment Group
The purpose of this study is to examine changes in the market for therapeutics used in the treatment of advanced lung cancer by examining longitudinal ...
See all reports like this >>

More United States Oncology/Hematology reports

US Cancer Diagnostics Market: Innovative Technologies and Emerging Business Opportunities by Venture Planning Group
This report contains 620 pages, 103 tables and presents a comprehensive analysis of the US cancer diagnostics market, including: Major issues pertaining to the US laboratory ...
US Proton Therapy Market Analysis to 2017 by RNCOS
According to most Oncologists, about 60% of all cancer patients undergo some sort of radiation therapy during their course of treatment. Despite advances in technology ...
United States Oncology Drug Delivery Preferences and Opportunities in Cancer Drug Delivery by Frost & Sullivan
Drug delivery is an important area of drug development in the pharmaceutical and biotechnology industry. In Oncology, developers are interested in understanding the opportunities and ...
The US Hematology Market: Instrument and Consumable Sales Forecasts by Market Segment, Key Supplier Shares by Venture Planning Group
This report provides an overview of the US hematology market, including sales and market shares of leading instrument and consumable suppliers, as well as test ...
See all reports like this >>

More United States reports

D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Coal - US - a snapshot (2010) by Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...
See all reports like this >>